Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

En studie för att bedöma biverkningar och hur intravenöst (IV) infunderat Telisotuzumab Vedotin (ABBV-399) rör sig genom kroppen som monoterapi hos vuxna deltagare med tidigare behandlad icke-småcellig, icke-småcellig lungcancer (NSCLC)

20 oktober 2026 uppdaterad av: AbbVie

En fas 2, öppen, randomiserad, global studie av två telisotuzumab-vedotinregimer hos patienter med tidigare behandlad c-Met-överuttryckande, EGFR-vildtyp, lokalt avancerad/metastaserande icke-skivepitelcancer, icke-småcellig lungcancer

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study is to assess how safe telisotuzumab vedotin is in adult participants with NSCLC. Change in disease activity and adverse events will be assessed.

Telisotuzumab vedotin is an investigational drug being developed for the treatment of NSCLC. Participants will be randomly assigned a treatment of telisotuzumab vedotin in 1 of 3 arms at an 1:1:1 ratio. Each group receives intravenous (IV) infusion of telisotuzumab vedotin at different doses. Approximately 150 adult participants with c-Met overexpressing NSCLC will be enrolled in the study at approximately 80 to 90 sites worldwide.

Participants will receive IV telisotuzumab vedotin at 1 of 3 dose regimens as part of a 3 year study duration.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Studieöversikt

Status

Rekrytering

Intervention / Behandling

Studietyp

Interventionell

Inskrivning (Beräknad)

150

Fas

  • Fas 2

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

      • São Paulo, Brasilien, 01323-020
        • Rekrytering
        • Hospital Alemao Oswaldo Cruz - Sao Paulo /ID# 272512
    • Ceará
      • Fortaleza, Ceará, Brasilien, 60810-180
        • Rekrytering
        • Suporte Nutricional e Quimioterapia LTDA - PRONUTRIR /ID# 273203
    • Paraná
      • Curitiba, Paraná, Brasilien, 80510-130
        • Rekrytering
        • Ictrials Pesquisa E Desenvolvimento /ID# 276681
    • Pará
      • Belém, Pará, Brasilien, 66063-495
        • Rekrytering
        • Cto - Centro De Tratamento Oncologico /ID# 276699
    • Pernambuco
      • Recife, Pernambuco, Brasilien, 50040-000
        • Rekrytering
        • Hospital De Cancer De Pernambuco /ID# 276104
    • Rio Grande do Norte
      • Natal, Rio Grande do Norte, Brasilien, 59075-740
        • Rekrytering
        • Liga Norte Riograndense Contra O Cancer /ID# 273183
    • Rio Grande do Sul
      • Ijuí, Rio Grande do Sul, Brasilien, 98700-000
        • Rekrytering
        • Oncosite - Centro de Pesquisa Clinica em Oncologia /ID# 272513
    • Santa Catarina
      • Florianópolis, Santa Catarina, Brasilien, 88020-210
        • Rekrytering
        • Cepen - Centro De Pesquisa E Ensino Em Oncologia De Santa Catarina /ID# 273204
    • Arizona
      • Chandler, Arizona, Förenta staterna, 85224
        • Rekrytering
        • Ironwood Cancer and Research Center /ID# 276370
    • Arkansas
      • Little Rock, Arkansas, Förenta staterna, 72205
        • Rekrytering
        • University of Arkansas for Medical Sciences /ID# 272923
    • California
      • Los Angeles, California, Förenta staterna, 90067
        • Rekrytering
        • Valkyrie Clinical Trials /ID# 271322
      • Los Angeles, California, Förenta staterna, 90025
        • Rekrytering
        • Start Los Angeles /ID# 284999
      • Oxnard, California, Förenta staterna, 93030
        • Rekrytering
        • FOMAT Medical Research - Clinica mi Salud by Focil Med /ID# 284816
    • Connecticut
      • New Haven, Connecticut, Förenta staterna, 06510
        • Avslutad
        • Yale New Haven Hospital /ID# 271584
    • Florida
      • Jacksonville, Florida, Förenta staterna, 32256
        • Rekrytering
        • Cancer Specialists of North Florida - Jacksonville - AC Skinner Parkway /ID# 270899
      • Ocala, Florida, Förenta staterna, 34474
        • Rekrytering
        • Ocala Oncology Center /ID# 273697
      • Pembroke Pines, Florida, Förenta staterna, 33028
        • Rekrytering
        • Memorial Hospital West /ID# 270313
      • St. Petersburg, Florida, Förenta staterna, 33701-4732
        • Rekrytering
        • Comprehensive Hematology Oncology /ID# 270422
      • St. Petersburg, Florida, Förenta staterna, 33705
        • Rekrytering
        • Florida Cancer Specialists - North /ID# 271995
      • West Palm Beach, Florida, Förenta staterna, 33401
        • Rekrytering
        • Florida Cancer Specialists - East /ID# 271993
    • Georgia
      • Athens, Georgia, Förenta staterna, 30607
        • Rekrytering
        • University Cancer and Blood Center /ID# 270969
      • Marietta, Georgia, Förenta staterna, 30060
        • Rekrytering
        • Northwest Georgia Oncology Centers /ID# 275374
      • Savannah, Georgia, Förenta staterna, 31404
        • Avslutad
        • Memorial University Medical Center /ID# 272467
    • Hawaii
      • Honolulu, Hawaii, Förenta staterna, 96819
        • Rekrytering
        • Kaiser Permanente Moanalua Medical Center /ID# 272916
    • Illinois
      • Chicago, Illinois, Förenta staterna, 60607
        • Rekrytering
        • University of Illinois Hospital and Health Sciences System /ID# 275345
      • Niles, Illinois, Förenta staterna, 60714
        • Rekrytering
        • Illinois Cancer Specialists /ID# 274678
      • Peoria, Illinois, Förenta staterna, 61637-0001
        • Rekrytering
        • OSF St. Francis Medical Center /ID# 281591
      • Springfield, Illinois, Förenta staterna, 62702
        • Rekrytering
        • Springfield Clinic - First /ID# 272576
    • Nebraska
      • Lincoln, Nebraska, Förenta staterna, 68506
        • Rekrytering
        • Nebraska Hematology-Oncology /ID# 272970
      • Omaha, Nebraska, Förenta staterna, 68130
        • Rekrytering
        • Nebraska Cancer Specialists - Omaha - Wright Street /ID# 271527
    • Nevada
      • Reno, Nevada, Förenta staterna, 89502
        • Rekrytering
        • Renown Regional Medical Center /ID# 273535
    • New Jersey
      • East Brunswick, New Jersey, Förenta staterna, 08816-4096
        • Rekrytering
        • Astera Cancer Care /ID# 272359
      • Teaneck, New Jersey, Förenta staterna, 07666
        • Rekrytering
        • Regional Cancer Care Associates /ID# 270783
    • New York
      • The Bronx, New York, Förenta staterna, 10461
        • Rekrytering
        • Montefiore Medical Center - Einstein Campus /ID# 277169
      • Westbury, New York, Förenta staterna, 11590
        • Rekrytering
        • Clinical Research Alliance (SMO/Network/Consortium) /ID# 270455
    • North Carolina
      • Pinehurst, North Carolina, Förenta staterna, 28374
        • Rekrytering
        • FirstHealth of the Carolinas- Speciality Center /ID# 272924
    • Ohio
      • Perrysburg, Ohio, Förenta staterna, 43551
        • Rekrytering
        • Mercy Health - Perrysburg Cancer Center /ID# 270536
      • Zanesville, Ohio, Förenta staterna, 43701
        • Rekrytering
        • Genesis Healthcare System /ID# 273361
    • Pennsylvania
      • Sayre, Pennsylvania, Förenta staterna, 18840
        • Rekrytering
        • Guthrie Robert Packer Hospital /ID# 270316
      • York, Pennsylvania, Förenta staterna, 17403
        • Rekrytering
        • Cancer Care Associates Of York /ID# 270971
    • South Carolina
      • Charleston, South Carolina, Förenta staterna, 29425
        • Rekrytering
        • Medical University of South Carolina /ID# 273272
      • Greenville, South Carolina, Förenta staterna, 29607
        • Rekrytering
        • Saint Francis Cancer Center - Greenville /ID# 276368
    • Tennessee
      • Nashville, Tennessee, Förenta staterna, 37203
        • Rekrytering
        • SCRI Oncology Partners /ID# 270162
    • Texas
      • Dallas, Texas, Förenta staterna, 75246
        • Rekrytering
        • Texas Oncology - Dallas - Worth Street /ID# 278947
      • Tyler, Texas, Förenta staterna, 75702
        • Rekrytering
        • Texas Oncology - Northeast Texas /ID# 272000
    • Utah
      • Ogden, Utah, Förenta staterna, 84405
        • Rekrytering
        • Community Cancer Trials Of Utah /ID# 276598
    • Virginia
      • Fairfax, Virginia, Förenta staterna, 22031
        • Rekrytering
        • Virginia Cancer Specialists - Fairfax /ID# 272004
    • Washington
      • Spokane, Washington, Förenta staterna, 99208
        • Rekrytering
        • Medical Oncology Associates - Spokane /ID# 277172
      • Tacoma, Washington, Förenta staterna, 98405
        • Rekrytering
        • Northwest Medical Specialties Tacoma /ID# 270534
      • Haifa, Israel, 3109601
        • Rekrytering
        • Rambam Health Care Campus- Haifa /ID# 270078
      • Jerusalem, Israel, 9103102
        • Avslutad
        • Shaare Zedek Medical Center /ID# 270095
    • Central District
      • Kefar Sava, Central District, Israel, 4428164
        • Rekrytering
        • Meir Medical Center /ID# 270071
      • Petah Tikva, Central District, Israel, 4941492
        • Rekrytering
        • Rabin Medical Center. /ID# 270087
    • Tel Aviv
      • Ramat Gan, Tel Aviv, Israel, 5265601
        • Rekrytering
        • The Chaim Sheba Medical Center /ID# 270068
    • Aichi-ken
      • Nagoya, Aichi-ken, Japan, 466-8560
        • Rekrytering
        • Nagoya University Hospital /ID# 277010
    • Chiba
      • Kashiwa-shi, Chiba, Japan, 277-8577
        • Rekrytering
        • National Cancer Center Hospital East /ID# 277056
    • Hokkaido
      • Sapporo, Hokkaido, Japan, 060-8648
        • Rekrytering
        • Hokkaido University Hospital /ID# 277014
    • Hyōgo
      • Kobe, Hyōgo, Japan, 650-0046
        • Rekrytering
        • Kobe Minimally Invasive Cancer Center /ID# 277469
    • Kanagawa
      • Sagamihara-shi, Kanagawa, Japan, 252-0375
        • Rekrytering
        • Kitasato University Hospital /ID# 277012
    • Miyagi
      • Sendai, Miyagi, Japan, 981-0914
        • Rekrytering
        • Sendai Kousei Hospital /ID# 277023
    • Miyazaki
      • Miyazaki, Miyazaki, Japan, 889-1692
        • Rekrytering
        • University of Miyazaki Hospital /ID# 277020
    • Okayama-ken
      • Kurashiki-shi, Okayama-ken, Japan, 710-8602
        • Rekrytering
        • Kurashiki Central Hospital /ID# 276995
    • Shizuoka
      • Fujieda, Shizuoka, Japan, 426-0077
        • Rekrytering
        • Fujieda Municipal General Hospital /ID# 277025
    • Wakayama
      • Wakayama, Wakayama, Japan, 641-8510
        • Rekrytering
        • Wakayama Medical University Hospital /ID# 276997
    • Beijing Municipality
      • Beijing, Beijing Municipality, Kina, 101149
        • Rekrytering
        • Beijing Chest Tumor Hospital /ID# 271935
    • Fujian
      • Fuzhou, Fujian, Kina, 350014
        • Rekrytering
        • Fujian Province Cancer Hospital /ID# 276178
    • Guangxi
      • Nanning, Guangxi, Kina, 530021
        • Rekrytering
        • Affiliated Cancer Hospital of Guangxi Medical University /ID# 271931
    • Heilongjiang
      • Harbin, Heilongjiang, Kina, 150081
        • Rekrytering
        • Harbin Medical University Cancer Hospital /ID# 271665
    • Henan
      • Zhengzhou, Henan, Kina, 450008
        • Rekrytering
        • Henan Cancer Hospital /ID# 271927
    • Hubei
      • Wuhan, Hubei, Kina, 430022
        • Rekrytering
        • Union Hospital - Tongji Medical College /ID# 271668
    • Jiangxi
      • Nanchang, Jiangxi, Kina, 330006
        • Rekrytering
        • The First Affiliated Hospital of Nanchang University /ID# 271666
    • Shaanxi
      • Xi'an, Shaanxi, Kina, 710061
        • Rekrytering
        • The First Affiliated Hospital of Xi'an Jiaotong University /ID# 271928
    • Shandong
      • Linyi, Shandong, Kina, 276001
        • Rekrytering
        • LinYi Cancer Hospital /ID# 272068
    • Xinjiang
      • Ürümqi, Xinjiang, Kina, 830011
        • Rekrytering
        • Cancer Hospital Affliated to Xinjiang Medical University /ID# 271933
    • Beograd
      • Belgrade, Beograd, Serbien, 11000
        • Rekrytering
        • Institute for Oncology and Radiology of Serbia /ID# 270561
      • Belgrade, Beograd, Serbien, 11080
        • Rekrytering
        • Clinical Hospital Center - Bezanijska Kosa /ID# 270558
      • Belgrade, Beograd, Serbien, 11000
        • Rekrytering
        • University Clinical Center Serbia /ID# 270808
      • Belgrade, Beograd, Serbien, 11000
        • Rekrytering
        • Military Medical Academy /ID# 279873
    • Nisavski Okrug
      • Niš, Nisavski Okrug, Serbien, 18300
        • Rekrytering
        • University Clinical Center Nis /ID# 270557
    • Sremski Okrug
      • Kamenitz, Sremski Okrug, Serbien, 21208
        • Rekrytering
        • Institute For Pulmonary Diseases Of Vojvodina /ID# 270559
    • Sumadijski Okrug
      • Kragujevac, Sumadijski Okrug, Serbien, 34000
        • Rekrytering
        • University Clinical Center Kragujevac /ID# 275773
    • Central Singapore
      • Singapore, Central Singapore, Singapore, 169611
        • Rekrytering
        • National Cancer Centre Singapore /ID# 271499
      • Singapore, Central Singapore, Singapore, 119074
        • Rekrytering
        • National University Hospital /ID# 271700

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Projected life expectancy of at least 12 weeks.
  • Must have c-Met overexpressing non-small cell lung cancer (NSCLC) (defined as >= 25% tumor cells with 3+ staining (high [>= 50% 3+]; intermediate [>= 25% - < 50%]) as assessed by a Sponsor designated immunohistochemistry (IHC) laboratory
  • Must have histologically or cytologically documented NSCLC that is locally advanced or metastatic.
  • Must have a known epidermal growth factor receptor (EGFR) activating mutation status.
  • Actionable alterations in genes other than EGFR are permitted.
  • Must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
  • Must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1.
  • Must have received no more than 1 line of prior systemic cytotoxic chemotherapy in the locally advanced or metastatic setting, as stated in the protocol.
  • Must have progressed on at least 1 line of prior therapy for locally advanced/metastatic NSCLC, as stated in the protocol.

Exclusion Criteria:

  • Adenosquamous or neuroendocrine histology, or sarcomatoid features.
  • EGFR activating mutations (e.g., EGFR Exon 19 deletions, T790M, Exon 21 L858R, or Exon 20 insertion mutations).
  • Received prior c-Met-targeted antibodies, prior telisotuzumab vedotin, or prior antibody-drug conjugates either targeting c-Met or consisting of monomethylauristatin E.
  • Received prior docetaxel therapy.
  • Metastases to the central nervous system (CNS). Participants with CNS metastases are eligible only after adequate treatment (such as surgery or, radiotherapy, or drug therapy) is provided, as stated on the protocol.
  • History of other malignancies except those stated in the protocol.
  • History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan, as noted in the protocol.
  • Unresolved clinically significant adverse event (AE) >= Grade 2 from prior anticancer therapy, except for alopecia or anemia. Participants with hormone deficiencies caused by prior anticancer therapy who are asymptomatic and on a stable dose of replacement hormone are eligible for study.
  • Major surgery within 21 days prior to randomization.
  • Clinically significant condition(s) including but not limited to those listed in the protocol.
  • Clinically significant liver disease, including hepatitis, current alcohol abuse, or cirrhosis.
  • Grade >= 2 edema or lymphedema.
  • Grade >= 2 ascites or pleural effusion.
  • Grade >= 2 neuropathy.
  • Active uncontrolled bacterial or viral infection.
  • Active corneal disorder.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Telisotuzumab Vedotin Dose A

Participants will receive telisotuzumab vedotin dose A, as part of the 3 year study duration.

Intravenous (IV) Infusion

Andra namn:
  • ABBV-399
Experimentell: Telisotuzumab Vedotin Dose B

Participants will receive telisotuzumab vedotin dose B, as part of the 3 year study duration.

Intravenous (IV) Infusion

Andra namn:
  • ABBV-399
Experimentell: Telisotuzumab Vedotin Dose C

Participants will receive telisotuzumab vedotin dose C, as part of the 3 year study duration.

Intravenous (IV) Infusion

Andra namn:
  • ABBV-399

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Percentage of Participants with Treatment-Emergent Adverse Events (AE)s (Any-grade and Grade >= 2)
Tidsram: Up to Approximately 3 Years

An AE is defined as any untoward medical occurrence, inappropriate participant management decision, unintended disease or injury or any untoward clinical signs (including an abnormal laboratory finding) in participants, users or other persons whether or not related to the investigational medical device.

Up to Approximately 3 Years
Percentage of Participants with Treatment-Emergent Interstitial Lung Disease (ILD)
Tidsram: Up to Approximately 3 Years

ILD is defined by ILD standardized MedDRA query (SMQ) (broad) per investigator and determined per adjudication (any-grade and Grade >= 2).

Up to Approximately 3 Years
Percentage of Participants with Treatment-Emergent Peripheral Neuropathy
Tidsram: Up to Approximately 3 Years

Peripheral neuropathy is defined by peripheral neuropathy SMQ (narrow) (any-grade and Grade >= 2)

Up to Approximately 3 Years
Percentage of Participants with Treatment-Emergent Ocular Surface Disorders
Tidsram: Up to Approximately 3 Years

Treatment-emergent ocular surface disorders defined by corneal epitheliopathy company MedDRA query (CMQ) (any-grade and Grade >= 2).

Up to Approximately 3 Years
Percentage of Participants with Treatment-Emergent AEs Leading to Study Drug Discontinuation
Tidsram: Up to Approximately 3 Years

An AE is defined as any untoward medical occurrence, inappropriate participant management decision, unintended disease or injury or any untoward clinical signs (including an abnormal laboratory finding) in participants, users or other persons whether or not related to the investigational medical device.

Up to Approximately 3 Years
Percentage of Participants with Grade 5 Treatment-Emergent AEs
Tidsram: Up to Approximately 3 Years

An AE is defined as any untoward medical occurrence, inappropriate participant management decision, unintended disease or injury or any untoward clinical signs (including an abnormal laboratory finding) in participants, users or other persons whether or not related to the investigational medical device.

Up to Approximately 3 Years
Objective Response (OR) by Blinded Independent Central Review (BICR)
Tidsram: Up to Approximately 3 Years

OR will be defined as achieving confirmed complete response (CR) or confirmed partial response (PR) based on response evaluation criteria in solid tumors (RECIST), version 1.1.

Up to Approximately 3 Years

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Concentrations of Telisotuzumab Vedotin Conjugate in Serum
Tidsram: Up to 26 Weeks

Concentrations of telisotuzumab vedotin conjugate in serum.

Up to 26 Weeks
Concentrations of Monomethylauristatin E (MMAE) Payload in Plasma
Tidsram: Up to 26 Weeks

Concentrations of MMAE payload in plasma.

Up to 26 Weeks
Percentage of Participants with Antidrug Antibodies (ADAs) of Telisotuzumab Vedotin
Tidsram: Up to 26 Weeks

Percentage of participants with ADAs of telisotuzumab vedotin.

Up to 26 Weeks
Percentage of Participants with Neutralizing Antidrug Antibodies (nADAs) of Telisotuzumab Vedotin
Tidsram: Up to 26 Weeks

Percentage of participants with nADAs of telisotuzumab vedotin.

Up to 26 Weeks
Change in Selected items of the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Tidsram: Cycle 1: Day 1, Day 8, Cycle 2 D1 and D1 of Every Even Cycle Thereafter, Through 3 Years

The PRO-CTCAE is a patient-reported outcome measurement system developed to assess symptomatic toxicity in patients participating in cancer clinical trials. PRO-CTCAE includes 124 items representing 78 symptomatic toxicities drawn from the Common Terminology Criteria for Adverse Events (CTCAE). PRO-CTCAE items evaluate the symptom attributes of frequency, severity, interference, amount, presence/absence. All questions employ a 7-day recall period and are scored from 0 to 4 (or 0/1 for absent/present).

Cycle 1: Day 1, Day 8, Cycle 2 D1 and D1 of Every Even Cycle Thereafter, Through 3 Years
Change in GP5 item of the Functional Assessment of Cancer Therapy-General (FACT-G)
Tidsram: Cycle 1: Day 1, Day 8, Cycle 2 D1 and D1 of Every Even Cycle Thereafter, Through 3 Years

The GP5 item ("I am bothered by side effects of treatment") of FACT-G is used to assess overall treatment tolerability in patients by assessing the overall side effect impact on participants.

Cycle 1: Day 1, Day 8, Cycle 2 D1 and D1 of Every Even Cycle Thereafter, Through 3 Years
Duration of Response (DoR) by BICR
Tidsram: Up to Approximately 3 Years

DoR is defined for confirmed responders as the time from the participants' initial response (CR or PR) to the first occurrence of radiographic progression per RECIST v1.1 or death from any cause.

Up to Approximately 3 Years
Progression-Free Survival (PFS) by BICR
Tidsram: Up to Approximately 3 Years

PFS will be defined as the time from randomization to the first occurrence of radiographic progression based on RECIST version 1.1 or death from any cause.

Up to Approximately 3 Years
Overall Survival (OS)
Tidsram: Up to Approximately 3 Years

OS will be defined as the time from randomization to death from any cause.

Up to Approximately 3 Years

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Utredare

  • Studierektor: ABBVIE INC., AbbVie

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

20 januari 2025

Primärt slutförande (Beräknad)

1 februari 2028

Avslutad studie (Beräknad)

1 februari 2028

Studieregistreringsdatum

Först inskickad

22 augusti 2024

Först inskickad som uppfyllde QC-kriterierna

22 augusti 2024

Första postat (Faktisk)

23 augusti 2024

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

22 oktober 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

20 oktober 2026

Senast verifierad

1 oktober 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

IPD-planbeskrivning

AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Tidsram för IPD-delning

For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/

Kriterier för IPD Sharing Access

To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

IPD-delning som stöder informationstyp

  • STUDY_PROTOCOL
  • SAV

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

produkt tillverkad i och exporterad från U.S.A.

Ja

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera